Stock Analiz

QuidelOrtho Corp QDEL

Biotechnology: In Vitro & In Vivo Diagnostic Substances · data as of November 13, 2026

$10.74Market cap $737M
Open the interactive analysis →

QuidelOrtho Corp (QDEL) is a healthcare company listed in the US with a market value of about $737M. In the twelve months to September 27, 2026 it had revenue of $2.6B and net income of -$369M, a net margin of -14.2%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 10% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 54% below the current price.

About QuidelOrtho

QuidelOrtho is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances. Revenue went from $1.7B in 2020 to $2.7B in 2025, growth of about 10.4% a year. It was profitable in 3 of the last 6 years in our data. Its share count rose by 18% over three years (dilution for shareholders). It spends 7% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E12.5
P/FCF—
P/S0.3
P/B0.4
EV/EBITDA11.0
PEG—
Dividend yield0.00%
FCF yield-15.9%
Shareholder yield0.0%
Intrinsic value vs. price−54%

Growth and quality

Revenue growth (1 yr)-1.9%
Revenue growth (5 yrs, per year)10.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-11.5%
ROIC (5-yr avg.)-0.9%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$2.6B$2.7B$2.8B$3.0B$3.3B$1.7B$1.7B
Net income-$369M-$1.1B-$2.1B-$10M$549M$704M$810M
Free cash flow-$117M-$83M-$112M$71M$744M$513M$565M
EPS (diluted)$-5.39$-16.69$-30.54$-0.15$9.56$16.43$18.60
Net margin-14.2%-41.4%-73.7%-0.3%16.8%41.5%48.8%
ROIC—-15.1%-33.3%1.4%8.1%34.2%62.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $15.00, 40% above the current price; targets range from $12.00 to $20.00; the consensus rating is “Hold”; expected EPS is $0.67 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is QuidelOrtho stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 54% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does QuidelOrtho pay a dividend?

Not currently.

Is QuidelOrtho a good stock to buy?

We do not give buy or sell advice. QuidelOrtho scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.